Tobevibart (VIR-3434) is an investigational broadly neutralizing monoclonal antibody in clinical development for chronic hepatitis delta, typically studied in combination with elebsiran. Phase 2 data reported high rates of undetectable HDV RNA and the registrational ECLIPSE program is ongoing with topline data expected in 2027. It is not approved for marketing.
Vir Biotechnology reported Q4 EPS of ($0.31), beating estimates by $0.23, with revenue of $64.07 million. The company announced a global strategic collaboration with Astellas for VIR-5500 and reported $781.6 million in cash and investments.
Vir Biotechnology announced a global strategic collaboration with Astellas for VIR-5500, a PSMA-targeted dual-masked T-cell engager for prostate cancer, and reported $781.6 million in cash and investments as of December 31, 2025.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07142811 |
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07128550 |
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide |
RECRUITING | PHASE3 |
| NCT06903338 |
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection |
ACTIVE_NOT_RECRUITING | PHASE3 |
